Toll-like receptor 9 agonists as cancer therapeutics

被引：53

作者：

Holtick, Udo ^{[1
,2
]}

Scheulen, Max E. ^{[3
]}

von Bergwelt-Baildon, Michael S. ^{[1
,2
]}

Weihrauch, Martin R. ^{[1
,2
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany

[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany

[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期

关键词：

cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;

D O I：

10.1517/13543784.2011.553187

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.

引用

页码：361 / 372

页数：12

共 50 条

[21] Synthesis and immunological activities of novel agonists of toll-like receptor 9
Struthers, Mary
Bett, Andrew J.
Wisniewski, Thomas
Dubey, Sheri A.
Precopio, Melissa
Jiang, Weiwen
Sun, Zhenhua
Wang, Hao
Nowak, Ireneusz
Putta, Mallikarjuna R.
Yu, Dong
Tang, Jimmy X.
Kandimalla, Ekambar R.
Agrawal, Sudhir
Casimiro, Danilo R.
CELLULAR IMMUNOLOGY, 2010, 263 (01) : 105 - 113
[22] Toll-like receptor 9 agonists delay apoptosis of human eosinophils
Ilmarinen, P.
Hasala, H.
Sareila, O.
Moilanen, E.
Kankaanranta, H.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2007, 65 (06) : 601 - 601
[23] Toll-like receptor 9 processing: The key event in Toll-like receptor 9 activation?
Bauer, Stefan
IMMUNOLOGY LETTERS, 2013, 149 (1-2) : 85 - 87
[24] The role of Toll-like receptor 9 in gynecologic cancer
Fehri, E.
Ennaifer, E.
Rhouma, R. Bel Haj
Guizani-Tabbane, L.
Guizani, I.
Boubaker, S.
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2016, 64 (03) : 155 - 159
[25] Toll-like receptor 7 agonists and skin
Novak, Natalija
Yu, Chun-Feng
Bieber, Thomas
Allam, Jean-Pierre
DRUG NEWS & PERSPECTIVES, 2008, 21 (03) : 158 - 165
[26] Toll-Like Receptor Agonists Are They Good Adjuvants?
Gnjatic, Sacha
Sawhney, Nikhil B.
Bhardwaj, Nina
CANCER JOURNAL, 2010, 16 (04): : 382 - 391
[27] Clinical investigations of Toll-like receptor agonists
Meyer, Thomas
Stockfleth, Eggert
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1051 - 1065
[28] Antiviral applications of Toll-like receptor agonists
Horscroft, Nigel J.
Pryde, David C.
Bright, Helen
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (04) : 789 - 801
[29] Toll-like receptor agonists in oncological indications
Aranda, Fernando
Vacchelli, Erika
Obrist, Florine
Eggermont, Alexander
Galon, Jerome
Sautes-Fridman, Catherine
Cremer, Isabelle
ter Meulen, Jan Henrik
Zitvogel, Laurence
Kroemer, Guido
Galluzzi, Lorenzo
ONCOIMMUNOLOGY, 2014, 3 (06):
[30] Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, Lorenzo
Vacchelli, Erika
Eggermont, Alexander
Fridman, Wolf Herve
Galon, Jerome
Sautes-Fridman, Catherine
Tartour, Eric
Zitvogel, Laurence
Kroemer, Guido
ONCOIMMUNOLOGY, 2012, 1 (05): : 699 - 716

← 1 2 3 4 5 →